Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PemBla: Intravesical vs Intravenous Pembrolizumab in NMIBC
NCT03167151Phase 2Terminated
- Sponsor
- University of Oxford
- Start
- Mar 2018
- Primary completion
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by University of Oxford. Started Mar 2018; status: terminated.
02
Drugs
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03167151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03167151.